Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma
April 23rd 2020Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).
Read More
Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL
January 31st 2020Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).
Read More
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC
Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512